Eli Lilly announced that Phase 2 TRAILBLAZER-ALZ results presented at the International Conference on Alzheimer’s & Parkinson Diseases and published simultaneously in the New England Journal of Medicine expand on previously reported top-line data that found donanemab met its primary endpoint and showed significant slowing of decline on the integrated Alzheimer’s Disease Rating Scale, a composite measure of cognition and daily function, in patients with early symptomatic Alzheimer’s disease compared to placebo. Additionally, data from secondary analyses showed donanemab consistently slowed cognitive and functional decline, with ranges between 20-40 percent in all secondary endpoints with nominal statistical significance at multiple times compared to placebo, Lilly said in a statement. Further, prespecified exploratory analyses showed donanemab slowed the accumulation of tau across key brain regions in patients affected by Alzheimer’s disease, it added. Specifically, at 76 weeks compared to baseline, treatment with donanemab slowed decline by 32% compared to placebo as measured by the iADRS, which was statistically significant. As early as nine months after initiation of treatment, a significant difference in decline by iADRS was observed, Lilly said. In addition, 40% of participants treated with donanemab achieved amyloid negativity as early as six months after starting treatment and 68% achieved this target by 18 months.